Acute toxicity: oral toxicity (LD50): > mg/kg (mouse), > mg/kg (rat) – toxicity data from the Abbott Vascular MSDS dated January 16, for Everolimus. SAFETY DATA SHEET. (in accordance with Regulation (EU) /). Everolimus. Version: 1. Revision date: 29/06/ Page 1 of. Material Safety Data Sheet. Section 1 – Product and Company Information. Product Name: Everolimus. Cat. Code: tlrl-eve. Company identification: InvivoGen.

Author: Mazuru Tet
Country: Trinidad & Tobago
Language: English (Spanish)
Genre: Sex
Published (Last): 7 May 2010
Pages: 122
PDF File Size: 16.91 Mb
ePub File Size: 14.17 Mb
ISBN: 317-3-53560-686-6
Downloads: 19041
Price: Free* [*Free Regsitration Required]
Uploader: Tojagul

Everolimus

Clofibrate The metabolism of Everolimus can be increased when combined with Clofibrate. Flunarizine The metabolism of Everolimus can be decreased when combined with Flunarizine. This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis.

Granisetron The metabolism of Everolimus can be decreased when combined with Granisetron. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Everolimus. Penicillamine The risk evdrolimus severity of adverse effects can be increased when Penicillamine is combined with Everolimus.

Aripiprazole The metabolism of Everolimus can be decreased when combined with Aripiprazole. Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Everolimus. Clotrimazole The metabolism of Everolimus can be increased when combined with Clotrimazole.

  ESCALA DE LILEY PDF

Haloperidol The metabolism of Everolimus can be decreased when combined with Haloperidol.

Dexlansoprazole The metabolism of Everolimus can be decreased when combined with Dexlansoprazole. Ganschow, Rainer, et al. Eperisone The metabolism of Everolimus can be decreased when combined with Eperisone. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Everolimus.

MSDS of Everolimus

Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Everolimus. Nintedanib The metabolism of Everoljmus can be decreased when combined with Nintedanib.

Englitazone The therapeutic efficacy of Englitazone can be decreased when used in combination with Everolimus.

Loperamide The serum concentration of Everolimus can be increased when it is combined with Loperamide. Nateglinide The metabolism of Everolimus can be decreased when combined with Nateglinide. Maraviroc The metabolism of Maraviroc can be decreased when combined with Everolimus.

Doxorubicin The serum concentration of Everolimus can be increased when it is combined with Doxorubicin. Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Everolimus. Insulin Glulisine The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Everolimus. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Everolimus.

  JEAN BAUDRILLARD THE ECSTASY OF COMMUNICATION PDF

Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor. Androstenedione The metabolism of Everolimus can be decreased when combined with Androstenedione. Indometacin The serum concentration of Everolimus can be increased when it is combined with Indometacin. Elvitegravir The metabolism of Everolimus can be decreased when combined with Elvitegravir. Glatiramer The risk or severity of adverse effects can be increased when Everolimus is combined with Glatiramer.

Chenodeoxycholic acid The metabolism of Everolimus can be decreased when combined with Chenodeoxycholic acid. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Everolimus.

Asenapine The metabolism of Everolimus can be decreased when combined with Asenapine. Gestrinone The metabolism of Everolimus can be decreased when combined with Gestrinone. Formocortal The risk or severity of adverse effects can be increased when Everolimus is combined with Formocortal. Hypoxanthine The metabolism of Hypoxanthine can be decreased when combined with Everolimus.

Last modified: April 20, 2020